UBS AM’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

UBS AM’s Portfolio BLCM Stock Details BLCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-3,556	Closed	-$120K	–	2889
2019 Q1	$120K	Buy	+3,556	New	+$119K	﹤0.01%	2552
2018 Q4	–	Sell	-2,490	Closed	-$153K	–	2837
2018 Q3	$153K	Hold	2,490	–	–	﹤0.01%	2494
2018 Q2	$184K	Buy	2,490 +170	+7%	+$13.3K	﹤0.01%	2495
2018 Q1	$152K	Buy	+2,320	New	+$175K	﹤0.01%	2425
2016 Q4	–	Sell	-1,050	Closed	-$209K	–	2711
2016 Q3	$209K	Hold	1,050	–	–	﹤0.01%	2446
2016 Q2	$136K	Hold	1,050	–	–	﹤0.01%	2546
2016 Q1	$98K	Buy	+1,050	New	+$114K	﹤0.01%	2570
2015 Q2	–	Sell	-8,970	Closed	-$2.08M	–	2730
2015 Q1	$2.08M	Sell	8,970 -100	-1%	-$24.2K	﹤0.01%	1344
2014 Q4	$2.09M	Buy	+9,070	New	+$1.95M	﹤0.01%	1308

Other funds holding BLCM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

UBS AM's BLCM Position: Q2 2019 in Review

UBS AM sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q2 2019, closing a stake of 3,556 shares — an estimated $120K sold.

UBS AM first reported a position in BLCM in Q4 2014 and held it in 9 quarters. The position peaked at $2.09M in Q4 2014. 79 funds tracked by Wall St. Rank hold BLCM as of Q2 2019.

UBS AM reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q2 2019 after selling out during the quarter.
UBS AM sold 3,556 Bellicum Pharmaceuticals, Inc. shares in Q2 2019, an estimated $120K.
UBS AM first reported a position in Bellicum Pharmaceuticals, Inc. in Q4 2014 and held it in 9 quarters.
UBS AM's Bellicum Pharmaceuticals, Inc. position peaked at $2.09M in Q4 2014.
79 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q2 2019.

Based on UBS AM's 13F filing for Q2 2019, filed 15 Aug 2019.